Recombinant Human VEGF-D Protein, CF | R&D Systems 622-VD-005/CF product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human VEGF-D Protein, CF

catalog :

622-VD-005/CF

quantity :

5 ug (also 25 ug)

price :

400 USD

citations: 9

Reference
Nishino K, Yoshimatsu Y, Muramatsu T, Sekimoto Y, Mitani K, Kobayashi E, et al. Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Sci Rep. 2021;11:8406 pubmed publisher
Nascimento E, Baldi B, Mariani A, Annoni R, Kairalla R, Pimenta S, et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res. 2018;19:83 pubmed publisher
Campbell K, Hadley D, Kukis D, Silva E. Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications. PLoS ONE. 2017;12:e0181484 pubmed publisher
Papiewska Pajak I, Balcerczyk A, Stec Martyna E, Koziołkiewicz W, Boncela J. Vascular endothelial growth factor-D modulates oxidant-antioxidant balance of human vascular endothelial cells. J Cell Mol Med. 2017;21:1139-1149 pubmed publisher
Fuchs C, Tabernero J, TomÃ¡Å¡ek J, Chau I, Melichar B, Safran H, et al. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016;115:974-982 pubmed publisher
Majumder M, Tutunea Fatan E, Xin X, Rodriguez Torres M, Torres Garcia J, Wiebe R, et al. Co-expression of ?9?1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE. 2012;7:e35094 pubmed publisher
Kilic N, Oliveira Ferrer L, Neshat Vahid S, Irmak S, Obst Pernberg K, Wurmbach J, et al. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1. Blood. 2007;110:4223-33 pubmed
Akahane M, Akahane T, Shah A, Okajima E, Thorgeirsson U. A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res. 2005;25:701-7 pubmed
Sun J, Phung T, Shiojima I, Felske T, Upalakalin J, Feng D, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102:128-33 pubmed

product information

master code :

622-VD/CF

SKU :

622-VD-005/CF

product name :

Recombinant Human VEGF-D Protein, CF

unit size :

5 ug (also 25 ug)

description :

The Recombinant Human VEGF-D Protein, CF from R&D Systems is derived from Sf 21 (baculovirus). The Recombinant Human VEGF-D Protein, CF has been validated for the following applications: Bioactivity, Binding Activity.

target :

VEGF-D

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

observed molecular weight :

10-20 kDa, reducing conditions

theoretical molecular weight :

13 kDa (monomer)

gene symbol :

FIGF

details of functionality :

Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al . (1999) Proc. Natl. Acad. Sci. USA 96 :9671. The ED50 for this effect is 0.1-0.3 ╡g/mL. Measured by its binding ability in a functional ELISA. Immobilized rhFlt-4/Fc Chimera at 5 ╡g/mL (100 ╡L/well) binds rhVEGF-D with an apparent KD 15 nM.

endotoxin note :

<1.0 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

O43915

applications :

Bioactivity, Binding Activity

source long :

Spodoptera frugiperda , Sf 21 (baculovirus)-derived human VEGF-D protein Phe93-Ser201, with an N-terminal Met and C-terminal 6-His tag

source short :

Sf 21 (baculovirus)

USD :

400 USD

alt names :

c-fos induced growth factor (vascular endothelial growth factor D), FIGF, vascular endothelial growth factor D, VEGFD, VEGF-DVEGFDc-Fos-induced growth factor

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.